Researcher
Michel Koole
- Disciplines:Medical imaging and therapy, Medicinal products
Affiliations
- Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Jan 2007 → Today
Projects
1 - 10 of 21
- A whole-body physiologically based pharmacokinetic model for personalized 161Tb-PRRTFrom1 Oct 2023 → TodayFunding: SCK (Study Centre Nuclear Energy)
- '213Bi-188Ready' Improved Theranostics with Bismuth-213 and Rhenium-188From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Fast quantitative SPECT imaging for patient specific dosimetry to facilitate personalized 177Lu-PSMA treatmentFrom18 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metrology for emerging targeted alpha therapiesFrom1 Sep 2023 → TodayFunding: H2020 - European Institute of Innovation and Technology
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- Low dose, high resolution Ga-68 PET imaging for oncological indicationsFrom25 May 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Innovative concepts for PET-MR imaging of brain function and brain-gut interactionsFrom14 Jan 2022 → TodayFunding: BOF - doctoral mandates
- Modelling of tumor control probability in preclinical targeted radionuclide therapyFrom1 Oct 2021 → TodayFunding: SCK (Study Centre Nuclear Energy)
- 18F-PSMA-1007 PET/MR imaging, quantification and radiomics in the primary staging of prostate cancer and response prediction after neoadjuvant hormonal therapyFrom1 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- "Dosimetry aspects of recoiling daughter nuclides of 225-Actinium in Targeted Alpha Therapy"From8 Nov 2019 → 15 Jul 2022Funding: SCK (Study Centre Nuclear Energy)
Publications
1 - 10 of 186
- Comparison of a 3D CZT and conventional SPECT/CT system for quantitative Lu-177 SPECT imaging.(2024)
Authors: Georg Schramm, Michel Koole
Pages: 29 - Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging.(2024)
Authors: Tom Van Loy, Christophe Deroose, Michel Koole, Dominique Schols, Frederik Cleeren
Pages: 108906 - Preliminary evidence for preserved synaptic density in late-life depression(2024)
Authors: Thomas Vande Casteele, Maarten Laroy, Margot Van Cauwenberge, Michel Koole, Patrick Dupont, Jan Van den Stock, Filip Bouckaert, Koen Van Laere, Louise Emsell, Mathieu Vandenbulcke
- Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside(2024)
Authors: Michel Koole, Christophe Deroose, Kristof Baete, Thomas Elias Cocolios, Frederik Cleeren
Pages: 1720 - 1743 - Tau Imaging in Late Traumatic Brain Injury: A [18F]MK-6240 Positron Emission Tomography Study(2024)
Authors: Greet Vanderlinden, Michel Koole, Robin Lemmens, Bart Depreitere, Mathieu Vandenbulcke, Koen Van Laere
Pages: 420 - 429 - PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management(2024)
Authors: Alexander Giesen, Steven Joniau, Koen Van Laere, Michel Koole, Christophe Deroose, Karolien Goffin
Pages: 31 - 54 - The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe(2023)
Authors: Michel Koole
Pages: 20 - 24 - Uncertainty analysis for Lu-177-PSMA in clinical routine(2023)
Authors: Michel Koole
Pages: S192 - S192 - Impact on clinical management when using [18F]AlFNOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results(2023)
Authors: Jeroen Dekervel, Frederik Cleeren, Michel Koole, Guy Bormans, Chris Verslype, Christophe Deroose
Pages: S508 - S508 - PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL)(2023)
Authors: Michel Koole
Pages: 2927 - 2934